What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
ABECMA is a chimeric antigen receptor (CAR) T cell therapy—a treatment for multiple myeloma (MM) unlike anything you may have received before. CAR T cell therapies are made from your own T cells that have been reprogrammed to find and destroy specific target cells, which may include cancer cells and normal cells.
*CAR T cell therapies find and destroy specific target cells, which may include cancer cells and normal cells.
BCMA=B-cell maturation antigen; CARs=chimeric antigen receptors.
A stem cell transplant (SCT) is another type of cell therapy that is commonly used to treat cancers of the blood, like MM.
See more details about the ABECMA Treatment Process.